Abcam, a global innovator in life science reagents and tools, is pleased to announce its move to new state-of-the-art global headquarters, Discovery Drive, on the Cambridge Biomedical Campus (CBC), UK, a leading hub of healthcare, science and medical research.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190227005291/en/
Abcam's new state-of-the-art global headquarters (Photo: Business Wire)
Alan Hirzel, CEO, Abcam, commented: “Abcam has been working for 20 years providing biological reagents and tools to help our customers accelerate research, and develop diagnostics and therapeutics that could revolutionise healthcare outcomes. Moving to Discovery Drive is integral to our mission to best serve the global life science community.”
With sites across the US, Europe and Asia in the world’s leading life science research hubs, Abcam’s move to Discovery Drive will combine three existing UK sites. Bringing all employees together, including R&D, laboratory, logistics, corporate and commercial functions, will facilitate open collaboration between teams to improve efficiency and innovation.
To support the Company’s continued growth, the new building provides 75% more space, features fully flexible laboratory configurations, and has new instrumentation and technology for enhanced scientific capabilities. It has also been designed to support agile working and provide introvert and extrovert workspaces.
In addition, the building has been developed to meet global sustainability standards, help protect the natural environment and enhance employee wellbeing.
- ENDS -
Notes to Editors
As a global life sciences company, Abcam identifies, develops, and distributes high-quality biological reagents and tools that are crucial to research, drug discovery and diagnostics. Working across the industry, the Company supports life scientists to achieve their mission, faster.
Abcam partners with life science organisations to co-create novel binders for use in drug discovery, in vitro diagnostics and therapeutics, driven by the Company’s proprietary discovery platforms and world-leading, antibody expertise.
By constantly innovating its binders and assays, Abcam is helping advance the global understanding of biology and causes of disease, which enables new treatments and improved health. The Company’s pioneering data-sharing approach gives scientists increased confidence in their results by providing validation, user comments and peer-reviewed citations for its 110,000 products.
With nine sites globally, many of Abcam’s 1,100 strong team are located in the world's leading life science research hubs, complementing a global network of services and support.
T: +44 (0)1223 696000